Question 1

What do medical sources say about Dextromethorphan during pregnancy?

Accepted Answer

1st Trimester: MotherToBaby says dextromethorphan taken as directed for cough is not expected to raise the chance of birth defects, and its sheet says a study of 128 first-trimester users did not report more miscarriages. The 2001 primary study reports 184 exposed pregnancies overall, including 128 first-trimester exposures, 10 spontaneous abortions, and one stillbirth, but its abstract does not give a separate miscarriage count for the 128-person subgroup. A 2021 case-control study found associations for hydrocephalus, atrioventricular septal defect, and transverse limb deficiency in its dextromethorphan-without-guaifenesin group, but 96.8% in that group also reported cough medicines with other active ingredients, and the authors said findings could be chance. These results differ from MotherToBaby's broad conclusion, while the single-ingredient capsule label advises a health-professional discussion before use; the label does not state that harm is established. MotherToBaby says alcohol-containing liquids are not recommended during pregnancy, and multi-symptom products and AUVELITY have separate ingredients and labeling. Ask your provider about your situation. 2nd Trimester: MotherToBaby describes pregnancy-wide evidence and says use as directed for cough is not expected to raise the chance of birth defects. The 2001 study reports outcomes for pregnancies exposed at any time, but does not give a separate second-trimester result. The 2021 case-control study reported early-pregnancy associations for hydrocephalus, atrioventricular septal defect, and transverse limb deficiency in its dextromethorphan-without-guaifenesin category; most users in that group also reported other medicine ingredients, and the authors said some findings could be chance. MotherToBaby says studies have not answered whether dextromethorphan affects preterm delivery or later learning and behavior, and says alcohol-containing liquids are not recommended in pregnancy. The single-ingredient capsule label advises consultation before use; the current Mucinex 12HR Cold & Fever Multi-Symptom label warns not to use its naproxen at 20 weeks or later unless a doctor specifically directs it, because it may cause problems in the unborn child or complications during delivery. Ask your provider about your situation. 3rd Trimester: MotherToBaby describes pregnancy-wide information, not a separate third-trimester estimate, and says use as directed for cough is not expected to raise birth-defect chance. The 2001 study includes pregnancies exposed at any time but reports no third-trimester-specific outcomes. The 2021 case-control study examined early pregnancy and reported associations for hydrocephalus, atrioventricular septal defect, and transverse limb deficiency; its dextromethorphan-without-guaifenesin category usually included other active ingredients, and the authors said some findings could be chance. MotherToBaby says preterm delivery and later child behavior or learning have not been studied, and says alcohol-containing liquids are not recommended in pregnancy. The single-ingredient capsule label advises consultation before use; the current Mucinex 12HR Cold & Fever Multi-Symptom label warns not to use its naproxen at 20 weeks or later unless a doctor specifically directs it, because it may cause problems in the unborn child or complications during delivery. Ask your provider about your situation.

Question 2

What do medical sources say about Dextromethorphan while breastfeeding?

Accepted Answer

LactMed says dextromethorphan and its active metabolite reach breast milk in very low amounts and are not expected to affect a nursing infant. Shum et al. measured milk and plasma after one 30 mg dose in 20 women at least 3 months postpartum and estimated relative infant doses below 1%. One nursing infant developed a rash during the study; the authors said the cause was unclear and more research is needed, while LactMed's 2025 page says relevant published infant-effect information was not found. MotherToBaby says short-term over-the-counter use as directed is not expected to cause problems for most breastfed infants and prefers alcohol-free cough syrups. The single-ingredient capsule label advises a health-professional discussion before use; AUVELITY is a different prescription combination whose label advises against breastfeeding during treatment and for 5 days after the final dose. Ask your provider about your situation.

Question 3

Where do sources disagree on Dextromethorphan in pregnancy or breastfeeding?

Accepted Answer

How to describe the birth-defect evidence for early-pregnancy dextromethorphan cough medicines MotherToBaby says directed cough use is not expected to raise the chance of birth defects; the Einarson and Martínez-Frías studies from 2001 did not find an increase. Cao et al. 2021 reported associations for hydrocephalus, atrioventricular septal defect, and transverse limb deficiency in its dextromethorphan-without-guaifenesin category. The current single-ingredient capsule label also tells pregnant users to ask a health professional before use. The Cao study tested multiple defect pairs with small exposed proportions, did not collect dose, and found that most mothers in the dextromethorphan-without-guaifenesin category also reported other active ingredients. Its authors said findings could be chance. The product label gives a consultation caution and does not state that harm has been established. The older studies are limited and do not resolve the newer signals. The available human studies do not establish a general causal increase across birth defects. Keep the compatible rating and 3 stars, while showing the 2021 signals, their limits, the label caution, and the distinction between cough products and combinations.

Dextromethorphan

Dextromethorphan — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources